Phase 2, Phase 3 Recruiting Network
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Florida: - Mount Sinai Comprehensive Cancer Center at Aventura — Aventura, Florida
- UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
- Holy Cross Hospital — Fort Lauderdale, Florida
Phase 2, Phase 3 Recruiting NIH
This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04402788
Sites in Florida: - Mount Sinai Comprehensive Cancer Center at Aventura — Aventura, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
- Mayo Clinic in Florida — Jacksonville, Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
Phase 3 Recruiting Academic/Other
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632327
Sites in Florida: - Orlando Health Cancer Institute - Lake Mary — Lake Mary, Florida
- The Watson Clinic — Lakeland, Florida
- Health Central — Ocoee, Florida
- Orlando Health Cancer Institute — Orlando, Florida
Phase 3 Recruiting NIH
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in Florida: - Moffitt Cancer Center-International Plaza — Tampa, Florida
- Moffitt Cancer Center - McKinley Campus — Tampa, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 3 Recruiting Network
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…
Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in Florida: - Golisano Children's Hospital of Southwest Florida — Fort Myers, Florida
- UF Health Cancer Institute - Gainesville — Gainesville, Florida
- Nemours Children's Clinic-Jacksonville — Jacksonville, Florida
- Nicklaus Children's Hospital — Miami, Florida
- Arnold Palmer Hospital for Children — Orlando, Florida
Phase 3 Recruiting Industry
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…
Sponsor: Pfizer
NCT ID: NCT07144280
Sites in Florida: - Cancer Care Centers of Brevard, Inc. — Palm Bay, Florida
- Florida Cancer Affiliates - Panama City — Panama City, Florida
Phase 3 Recruiting Industry
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in Florida: - Clinical Study Site — Fort Lauderdale, Florida
- Clinical Study Site — Hialeah, Florida
- Clinical Study Site — Jacksonville, Florida
- Clinical Study Site — Miami, Florida
- Clinical Study Site — North Venice, Florida
Phase 3 Recruiting Industry
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…
Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Sites in Florida: - Boca Raton Regional Hospital — Boca Raton, Florida
- Florida Cancer Specialists - South — Fort Myers, Florida
- University of Florida - Jacksonville — Jacksonville, Florida
- Miami Cancer Institute at Baptist Health, Inc. — Miami, Florida
- Ocala Oncology Center PL DBA Florida Cancer Affiliates - Ocala — Ocala, Florida
Phase 3 Recruiting Industry
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary en…
Sponsor: Summit Therapeutics
NCT ID: NCT05899608
Sites in Florida: - Florida Cancer Specialists & Research Institute (FCS)-East — Fort Myers, Florida
- BioResearch Partner- Hialeah Hospital — Hialeah, Florida
- Mayo Clinic — Jacksonville, Florida
- Cancer Specialists of North Florida — Jacksonville, Florida
- Ocala Oncology — Ocala, Florida
Phase 3 Recruiting Academic/Other
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…
Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in Florida: - UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
- UM Sylvester Comprehensive Cancer Center at Doral — Doral, Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
Phase 3 Recruiting Industry
TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable gen…
Sponsor: AstraZeneca
NCT ID: NCT07291037
Sites in Florida: - Research Site — Fort Myers, Florida
- Research Site — Jacksonville, Florida
- Research Site — St. Petersburg, Florida
- Research Site — Tampa, Florida
- Research Site — West Palm Beach, Florida
Phase 3 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…
Sponsor: AbbVie
NCT ID: NCT04928846
Sites in Florida: - Mayo Clinic Hospital Jacksonville /ID# 254688 — Jacksonville, Florida
- Ocala Oncology Florida Cancer Affiliates - Main /ID# 234228 — Ocala, Florida
- BRCR Medical Center Inc /ID# 262344 — Tamarac, Florida
Phase 3 Recruiting Industry
This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tir…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312137
Sites in Florida: - Mayo Clinic in Florida ( Site 0014) — Jacksonville, Florida
- Mount Sinai Cancer Center ( Site 0038) — Miami Beach, Florida
- Mid Florida Hematology and Oncology Center ( Site 0018) — Orange City, Florida
Phase 3 Recruiting Industry
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in Florida: - The Oncology Institute of Hope and Innovation - Fort Lauderdale ( Site 0156) — Fort Lauderdale, Florida
- Miami Cancer Institute at Baptist Health, Inc. ( Site 0214) — Miami, Florida
Phase 3 Recruiting Industry
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT06875310
Sites in Florida: - Local Institution - 0052 — Jacksonville, Florida
- Local Institution - 0680 — Ocala, Florida
- Local Institution - 0679 — Orange City, Florida
- Local Institution - 0621 — Palm Bay, Florida
- Local Institution - 0365 — Plantation, Florida
Phase 3 Recruiting Academic/Other
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT02468024
Sites in Florida: - Boca Raton Regional Hospital — Boca Raton, Florida
Phase 3 Recruiting Industry
The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).
Sponsor: Amgen
NCT ID: NCT07005128
Sites in Florida: - Orlando Health Cancer Institute — Kissimmee, Florida
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07063745
Sites in Florida: - Local Institution - 0152 — Fort Lauderdale, Florida
- Mayo Clinic in Florida — Jacksonville, Florida
- Local Institution - 0430 — St. Petersburg, Florida
Phase 3 Recruiting Industry
The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced o…
Sponsor: AstraZeneca
NCT ID: NCT06350097
Sites in Florida: - Research Site — Jacksonville, Florida
- Research Site — Ocala, Florida
- Research Site — Orange City, Florida
Phase 2, Phase 3 Recruiting Industry
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…
Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in Florida: - Clermont Oncology Center — Clermont, Florida
- Cleveland Clinic Florida - Martin North Hospital — Stuart, Florida
- H. Lee Moffit Cancer center and research institute — Tampa, Florida
- Cleveland Clinic Weston Hospital — Weston, Florida
Phase 3 Recruiting Academic/Other
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation thera…
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
NCT ID: NCT06095583
Sites in Florida: - Florida Cancer Specialists Pan Handle — Fort Myers, Florida
- Florida Cancer Specialists South — Fort Myers, Florida
- USA029 University of Miami Sylvester Comprehensive Cancer Center 1550 NW 10th Avenue 33173 Miami FL Ikpeazu Chukwuemeka N — Miami, Florida
- Mid-Florida Hematology Oncology — Orange City, Florida
Phase 2, Phase 3 Recruiting Industry
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07100080
Sites in Florida: - Local Institution - 0085 — Gainesville, Florida
- Local Institution - 0142 — Pembroke Pines, Florida
Phase 3 Recruiting Industry
This study is open to adults 18 years and older who have early-stage non-small cell lung cancer (NSCLC). Their cancer must have a specific change in a gene called HER2. Genes provide the instructions for making proteins, and this change le…
Sponsor: Boehringer Ingelheim
NCT ID: NCT07195695
Sites in Florida: - Mid Florida Hematology and Oncology Center — Orange City, Florida
Phase 3 Recruiting Industry
This is a randomized, open-label, phase 3 clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (experimental arm) versus docetaxel monotherapy (control arm). Enrolled participants will be randomized 2:…
Sponsor: ImmunityBio, Inc.
NCT ID: NCT06745908
Sites in Florida: - Holy Cross Hospital — Fort Lauderdale, Florida
- The Oncology Institute of Hope and Innovation — Fort Lauderdale, Florida
- Moffit Cancer Center — Tampa, Florida
Phase 3 Recruiting Industry
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (E…
Sponsor: Gilead Sciences
NCT ID: NCT06801834
Sites in Florida: - Boca Raton Regional — Miami, Florida